It is important to acknowledge that while LNCaP and PC-3 cell lines provided ideal PSMA-positive and PSMA-negative controls for this proof-of-concept study, they represent only a subset of the heterogeneous PSMA expression observed in clinical prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.